PNC-27 5 mg is used in experimental research to investigate its ability to target and kill cancer cells by disrupting their membranes, particularly in studies involving solid tumors. It is not approved for clinical use and is intended solely for laboratory or research purposes, requiring reconstitution before application.
The half-life of PNC-27 5 mg is approximately 6-8 hours in experimental models, though this can vary based on administration method, metabolism, and research conditions. Its relatively short duration necessitates frequent dosing in studies, with detectable levels diminishing within 24-48 hours depending on the system.
PNC-27 5 mg is not established as safe for human use, as it is intended solely for research purposes. Potential risks in experimental settings include injection site reactions or systemic effects, with safety data limited to preclinical studies. Use is strictly for laboratory research under professional supervision, and it should not be used by individuals without medical oversight.
PNC-27 5 mg works by binding to HDM-2 protein on cancer cell membranes, forming pores that lead to cell lysis and death, while sparing healthy cells. This mechanism, derived from the p53 protein, targets malignant cells specifically, making it a focus of cancer research for potential therapeutic development.
PNC-27 has a half-life of approximately 6-8 hours, with its effects waning within 24-48 hours in experimental models, depending on dosage, administration route, and metabolic factors. Researchers should monitor clearance through appropriate assays, and professional guidance is advised for precise timelines.
PNC-27 binds to HDM-2 on cancer cell membranes, inducing pore formation and subsequent cell lysis, a process selective to malignant cells due to their unique membrane composition. This action mimics p53 tumor suppression, offering a targeted approach in research settings. Effects begin rapidly and are studied over short durations. What doesn't happen: no broad systemic impact, but monitoring is essential.
PNC-27 5 mg excels for researchers exploring cancer therapies, requiring controlled lab conditions to maximize its experimental potential.
Best for researchers in oncology or peptide studies; intended for laboratory use only, not for human consumption. Not recommended for personal use or those without research credentials.
| Substance | PNC-27 Anti-Cancer Peptide |
|---|---|
| Concentration | 5 mg |
| Form | Vial (requires reconstitution) |
| Pack Size | Vial |
| Half-life | ~6-8 hours |
| Aromatization/Hepatic | Non-applicable / Minimal hepatic |
| Primary Use | Cancer research |
| Manufacturer | Generic Peptides |
| Brand | PNC-27 |
PNC-28: Complements anti-cancer research.
IGF-1 LR3: May contrast growth vs. cancer effects.
TB-500: Supports tissue studies.
Cycle Support: Ensures lab safety protocols.
PNC-27 5 mg vs PNC-28: Both target cancer; PNC-27 is more studied.
PNC-27 5 mg vs Cisplatin: PNC-27 is peptide-based; Cisplatin is a chemo drug.
PNC-27 5 mg vs Taxol: PNC-27 targets membranes; Taxol affects microtubules.
Consult a research professional to ensure safe handling and monitor experimental outcomes.
What is the PNC-27 peptide used for?
PNC-27 is used for cancer research; see What is the PNC-27 Peptide Used for. For lab use only—consult professionals.
What is the half-life of PNC-27?
It has a 6-8 hour half-life; see What is the Half-Life of PNC-27. Study-specific—consult professionals.
Is PNC-27 safe?
Not for human use, for research only; see Is PNC-27 Safe. Handle with care—consult professionals.
How does PNC-27 work?
It kills cancer cells via membrane disruption; see How Does PNC-27 Work. Research use only—consult professionals.